Trials / Unknown
UnknownNCT03142646
Safety and Efficacy Evaluation of IM19 CAR-T Cells
Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 4 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.
Detailed description
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-ALL patients and determine the MTD,LTD and the best dosage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IM19 CAR-T | All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later. |
Timeline
- Start date
- 2016-08-30
- Primary completion
- 2018-06-01
- Completion
- 2018-10-01
- First posted
- 2017-05-05
- Last updated
- 2018-05-01
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03142646. Inclusion in this directory is not an endorsement.